Despite being first identified in the scientific literature in the 1920s, there are only four FDA-approved drugs to treat Glioblastoma (GBM). Four in 100 years. For Glioblastoma (GBM), the five-year relative survival rate is only 7.2% and median survival is only 8 months.
These devastating statistics attest to the underfunded and under-researched nature of brain cancer treatments – particularly treatments for high-grade gliomas (HGG).
The Knox Martin Foundation for Brain Cancer Research was created to fund the next breakthrough in brain cancer – particularly in aggressive brain cancers – giving warriors like Knox a longer life expectancy.
For more information on the Knox Martin Foundation, visit knoxmartinfoundation.org/
To attend the Knox Martin Foundation's signature event, Night for Knox, visit knoxmartinfoundation.org/nightforknox